Several digital therapeutics (DTx) — evidence-based interventions delivered via mobile app or web-based platforms — could help patients with irritable bowel syndrome (IBS), according to a new review of available products.
These tools aren’t widely used by gastroenterologists yet, but the market is expected to grow broadly during the next decade.
“Digital therapeutics make so much sense and solve so many access issues,” co-author William Chey, MD, chief of gastroenterology at the University of Michigan in Ann Arbor, told Medscape Medical News. “Because of this, their promise could easily outstrip their substance. We need to hold digital therapeutics companies accountable for proper evidence of benefit, so patients and doctors don’t end up chasing the latest shiny object.”